Randomized, controlled trials have thus far been negative. New therapeutic directions may be proposed selleck kinase inhibitor by investigating yet unexplored pathophysiologic processes. Tabibian et al. turned their attention to cellular senescence. Their results reveal that cholangiocytes of PSC patients express proteins and proinflammatory markers of senescence, in contrast to cholangiocytes of healthy controls. The researchers established an in vitro model of lipopolysaccharide-induced senescence of normal human cholangiocytes.

With this model, they could demonstrate induction of senescence in bystander cholangiocytes by senescent cholangiocytes. The researchers found that this senescence depends on N-ras and can be prevented by an N-ras inhibitor. These are provocative results. We are eager to know whether they can be translated into a benefit for patients with

PSC. (HEPATOLOGY; 2014;59:2263–2275.) The patatin-like phospholipase domain-containing JQ1 ic50 3 (PNPLA3) gene is a hot topic in hepatology. A single-nucleotide polymorphism (SNP) located in this gene has been consistently associated with progression of liver diseases, such as NASH, alcoholic liver disease (ALD), and CHC. This SNP has been associated with inflammation and fibrosis, two important features predisposing to hepatocellular carcinoma (HCC). In order to investigate whether this PNPLA3 SNP is also associated with HCC, Trépo et al. performed a meta-analysis based on 2,503 European patients with cirrhosis. Methodologically, 上海皓元医药股份有限公司 they were able to access the individual participant data. Their results indicated an association between the PNPLA3 SNP and HCC. The association was stronger in patients with ALD, but also significant in patients with CHC after adjustment for age, sex, and body mass index. However, the magnitude of the association is not sufficient to provide a biomarker for HCC surveillance based on this SNP. That said, the mechanism should be further investigated, especially for a gene whose function is still controversial. (HEPATOLOGY; 2014;59:2170–2177.) Transplantation is an excellent option for eligible patients with

HCC. These recipients are cured from the tumor and from cirrhosis. With the implementation of surveillance programs, more and more patients with HCC are listed. Wong et al. used the United Network for Organ Sharing registry to provide accurate numbers and proportions over a decade. From 2002 to 2012, the number of patients transplanted for HCC increased 10-fold, which represents a percentage increase from 3% to 23%. Not surprisingly, HCV was the leading etiology. NASH was the second etiology, but it was the most rapidly growing indication. It is only a matter of time for NASH to become the leading cause of HCC in transplanted patients, which is likely to come sooner with the development of new treatments against HCV. (HEPATOLOGY; 2014;59:2188–2195.